Suppr超能文献

新型吲达泊林相关二芳基吡咯衍生物的合成及抗乳腺癌活性。

Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives.

机构信息

Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, 1417614411, Iran.

Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.

出版信息

Daru. 2019 Jun;27(1):179-189. doi: 10.1007/s40199-019-00260-9. Epub 2019 Mar 20.

Abstract

BACKGROUND

During recent years, a number of anti-tubulin agents were introduced for treatment of diverse types of cancer. Despite their potential in the treatment of cancer, drug resistance and adverse toxicity, such as peripheral neuropathy, are some of the negative effects of anti-tubulin agents. Among anti-tubulin agents, indibulin was found to cause minimal peripheral neuropathy. Thus far, however, indibulin has not entered clinical usage, caused in part by its poor aqueous solubility and other developmental problems in preclinical evaluation.

OBJECTIVES

With respect to need for finding potent and safe anticancer agents, in our current research work, we synthesized several indibulin-related diarylpyrrole derivatives and investigated their anti-cancer activity.

METHODS

Cell cultur studies were perfomred using the MTT cell viability assay on the breast cancer cell lines MCF-7, T47-D, and MDA-MB231 and also NIH-3 T3 cells as representative of a normal cell line. The activity of some of the synthesized compounds for tubulin interaction was studied using colchicine binding and tubulin polymerization assays. The annexin V-FITC/PI method and flow cytometric analysis were used for studying apoptosis induction and cell cycle distribution.

RESULTS AND CONCLUSION

Two of the synthesized compounds, 4f and 4 g, showed high activity on the MDA-MB231 cell line (IC = 11.82 and 13.33 μM, (respectively) and low toxicity on the normal fibroblast cells (IC > 100 μM). All of the tested compounds were more potent on T47-D cancer cells and less toxic on NIH-3 T3 normal cells in comparison to reference compound, indibulin. The tubulin polymerization inhibition assay and [H]colchicine binding assay showed that the main mechanism of cell death by the potent synthesized compounds was not related to an interaction with tubulin. In the annexin V/PI staining assay, the induction of apoptosis in the MCF-7 and MDA-MB231 cell lines was observed. Cell cycle analysis illustrated an increased percentage of sub-G-1 cells in the MDA-MB231 cell line as a further indication of cell death through induction of apoptosis. Graphical abstract Novel Indibulin analogous as anti-breast cancer agents.

摘要

背景

近年来,许多抗微管蛋白药物被引入用于治疗多种类型的癌症。尽管它们在癌症治疗方面具有潜力,但药物耐药性和外周神经病变等不良反应也是抗微管蛋白药物的一些负面影响。在抗微管蛋白药物中,吲达布林被发现引起的外周神经病变最小。然而,吲达布林尚未进入临床应用,部分原因是其水溶性差和临床前评估中的其他开发问题。

目的

鉴于需要寻找有效且安全的抗癌药物,在我们目前的研究工作中,我们合成了几种吲达布林相关的二芳基吡咯衍生物,并研究了它们的抗癌活性。

方法

采用 MTT 细胞活力测定法,在乳腺癌细胞系 MCF-7、T47-D 和 MDA-MB231 以及 NIH-3T3 细胞(代表正常细胞系)中进行细胞培养研究。使用秋水仙碱结合和微管蛋白聚合测定法研究了一些合成化合物与微管蛋白相互作用的活性。采用 Annexin V-FITC/PI 法和流式细胞术分析研究细胞凋亡诱导和细胞周期分布。

结果与结论

在所合成的化合物中,有两种化合物 4f 和 4g 对 MDA-MB231 细胞系表现出高活性(IC50 值分别为 11.82 和 13.33 μM),对正常成纤维细胞的毒性较低(IC50>100 μM)。与参考化合物吲达布林相比,所有测试的化合物在 T47-D 癌细胞中的活性更强,对 NIH-3T3 正常细胞的毒性更低。微管蛋白聚合抑制试验和[H]秋水仙碱结合试验表明,有效合成化合物引起细胞死亡的主要机制与微管蛋白的相互作用无关。在 Annexin V/PI 染色试验中,观察到 MCF-7 和 MDA-MB231 细胞系中细胞凋亡的诱导。细胞周期分析表明,MDA-MB231 细胞系中亚 G1 期细胞的比例增加,进一步表明通过诱导细胞凋亡导致细胞死亡。

图 1 新型吲达布林类似物作为抗乳腺癌药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86da/6593016/26a1bfa65f04/40199_2019_260_Figa_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验